Novel Methylation-driven Genes Identified As Prognostic Indicators for Lung Squamous Cell Carcinoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2019 May 21

PMID 31105813

Citations 14

Authors

Yin Li

Jie Gu

Fengkai Xu

Qiaoliang Zhu

Di Ge

Chunlai Lu

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains the leading cause of cancer death. DNA methylation plays an essential role in carcinogenesis through regulating gene expression and gene alternative splicing. However, the role of methylation in the tumorigenesis of lung squamous cell carcinoma (SCC) and its association with prognosis remains unclear. Here, we used an integrative approach to evaluate the prognostic value of epigenetic processes in lung SCC by examining the data provided by The Cancer Genome Atlas (TCGA). We found that the mean methylation level was significantly decreased in lung SCC. We also identified methylation-driven genes which were associated with cancer-related pathways. The multivariate Cox regression analysis showed four methylation-driven genes, GCSAM, GPR75, NHLRC1, and TRIM58, could be served as prognostic indicators for lung SCC. Validation on two external GEO datasets showed consistent methylation alterations of the four genes. These findings may have important implications in the understanding of the potential therapeutic method for lung SCC.

Citing Articles

Global and endothelial G-protein coupled receptor 75 (GPR75) knockout relaxes pulmonary artery and mitigates hypoxia-induced pulmonary hypertension.

DAddario C, Matsumura S, Kitagawa A, Lainer G, Zhang F, DSilva M Vascul Pharmacol. 2023; 153:107235.

PMID: 37742819 PMC: 10841449. DOI: 10.1016/j.vph.2023.107235.

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer.

Han S, Jiang D, Zhang F, Li K, Jiao K, Hu J Front Oncol. 2023; 13:1095313.

PMID: 36793597 PMC: 9924230. DOI: 10.3389/fonc.2023.1095313.

Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.

Li S, Xue P, Diao X, Fan Q, Ye K, Tang X J Adv Res. 2023; 54:133-146.

PMID: 36716957 PMC: 10703616. DOI: 10.1016/j.jare.2023.01.010.

Identification of as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS).

Faltus C, Lahnsteiner A, Barrdahl M, Assenov Y, Husing A, Bogatyrova O Int J Mol Sci. 2022; 23(18).

PMID: 36142605 PMC: 9505874. DOI: 10.3390/ijms231810699.

Identification of a glycolysis-related gene signature associated with clinical outcome for patients with lung squamous cell carcinoma.

Xu Z, Zhang S, Nian F, Xu S Cancer Med. 2021; 10(12):4017-4029.

PMID: 33991070 PMC: 8209576. DOI: 10.1002/cam4.3945.

References

Vickers A, Elkin E . Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006; 26(6):565-74. PMC: 2577036. DOI: 10.1177/0272989X06295361. View

Lu X, Chen J, Malumbres R, Gil E, Helfman D, Lossos I . HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration. Blood. 2007; 110(13):4268-77. PMC: 2234785. DOI: 10.1182/blood-2007-04-087775. View

Devaney J, Stirzaker C, Qu W, Song J, Statham A, Patterson K . Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomarkers Prev. 2010; 20(1):148-59. DOI: 10.1158/1055-9965.EPI-10-0719. View

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

McCarthy D, Chen Y, Smyth G . Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res. 2012; 40(10):4288-97. PMC: 3378882. DOI: 10.1093/nar/gks042. View

Guo D, Wu B, Yan J, Li X, Sun H, Zhou D . A possible gene silencing mechanism: hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells. Biochem Biophys Res Commun. 2012; 428(1):80-5. DOI: 10.1016/j.bbrc.2012.10.010. View

Aberle D, Abtin F, Brown K . Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. J Clin Oncol. 2013; 31(8):1002-8. PMC: 3589698. DOI: 10.1200/JCO.2012.43.3110. View

Liu B, Hassan Z, Amisten S, King A, Bowe J, Huang G . The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis. Diabetologia. 2013; 56(11):2467-76. DOI: 10.1007/s00125-013-3022-x. View

Takebe N, Nguyen D, Yang S . Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2013; 141(2):140-9. PMC: 3982918. DOI: 10.1016/j.pharmthera.2013.09.005. View

10.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Javier Carmona F, Sayols S . A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 2013; 31(32):4140-7. DOI: 10.1200/JCO.2012.48.5516. View

11.

Ashktorab H, Daremipouran M, Goel A, Varma S, Leavitt R, Sun X . DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. Epigenetics. 2014; 9(4):503-12. PMC: 4121361. DOI: 10.4161/epi.27644. View

12.

Piperdi B, Merla A, Perez-Soler R . Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014; 74(4):403-13. PMC: 4014113. DOI: 10.1007/s40265-014-0182-z. View

13.

Toton E, Lisiak N, Sawicka P, Rybczynska M . Beclin-1 and its role as a target for anticancer therapy. J Physiol Pharmacol. 2014; 65(4):459-67. View

14.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

15.

Gevaert O, Tibshirani R, Plevritis S . Pancancer analysis of DNA methylation-driven genes using MethylMix. Genome Biol. 2015; 16:17. PMC: 4365533. DOI: 10.1186/s13059-014-0579-8. View

16.

Licht J . DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension. Cell. 2015; 162(5):938-9. DOI: 10.1016/j.cell.2015.08.005. View

17.

Yao L, Ren S, Zhang M, Du F, Zhu Y, Yu H . Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget. 2015; 6(38):40611-21. PMC: 4747356. DOI: 10.18632/oncotarget.6141. View

18.

Colaprico A, C Silva T, Olsen C, Garofano L, Cava C, Garolini D . TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2015; 44(8):e71. PMC: 4856967. DOI: 10.1093/nar/gkv1507. View

19.

Graff E, Fang H, Wanders D, Judd R . Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2. Metabolism. 2016; 65(2):102-13. DOI: 10.1016/j.metabol.2015.10.001. View

20.

Marwitz S, Depner S, Dvornikov D, Merkle R, Szczygiel M, Muller-Decker K . Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion. Cancer Res. 2016; 76(13):3785-801. DOI: 10.1158/0008-5472.CAN-15-1326. View